Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 10, 2025

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Zacks Investment Research • Nov 27, 2025

Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.

Seeking Alpha • Nov 26, 2025

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Zacks Investment Research • Nov 21, 2025

IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?

Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Zacks Investment Research • Nov 13, 2025

IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars

Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.

Zacks Investment Research • Nov 11, 2025

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ.

Business Wire • Nov 10, 2025

Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.

Zacks Investment Research • Nov 10, 2025

Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta

CALGARY, AB / ACCESS Newswire / October 24, 2025 / Ironwood Stair & Rail Inc., a company built on craftsmanship and passion, has been recognised with the 2025 Consumer Choice Award in the Stairs and Railings category for Southern Alberta. This recognition highlights Ironwood's reputation for exceptional design, quality, and service in transforming homes and businesses with custom-built stairs and railings.

Accesswire • Oct 24, 2025

Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Oct 14, 2025